217 related articles for article (PubMed ID: 33298588)
1. EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1.
Weadick B; Nayak D; Persaud AK; Hung SW; Raj R; Campbell MJ; Chen W; Li J; Williams TM; Govindarajan R
Mol Cancer Ther; 2021 Feb; 20(2):410-422. PubMed ID: 33298588
[TBL] [Abstract][Full Text] [Related]
2. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
3. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Espinoza JA; García P; Bizama C; Leal JL; Riquelme I; Weber H; Macanas P; Aguayo G; Viñuela E; Roa JC; Nervi B
Histopathology; 2016 Apr; 68(5):722-8. PubMed ID: 26266900
[TBL] [Abstract][Full Text] [Related]
4. Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Revalde JL; Li Y; Wijeratne TS; Bugde P; Hawkins BC; Rosengren RJ; Paxton JW
Eur J Pharmacol; 2017 May; 803():167-173. PubMed ID: 28365185
[TBL] [Abstract][Full Text] [Related]
5. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
6. Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Kuo YC; Kou HW; Hsu CP; Lo CH; Hwang TL
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108495
[TBL] [Abstract][Full Text] [Related]
7. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
Hu Q; Qin Y; Zhang B; Liang C; Ji S; Shi S; Xu W; Xiang J; Liang D; Ni Q; Yu X; Xu J
Oncol Rep; 2017 Oct; 38(4):2069-2077. PubMed ID: 28765935
[TBL] [Abstract][Full Text] [Related]
8. New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells.
Guillén-Gómez E; Pinilla-Macua I; Pérez-Torras S; Choi DS; Arce Y; Ballarín JA; Pastor-Anglada M; Díaz-Encarnación MM
J Cell Physiol; 2012 Apr; 227(4):1521-8. PubMed ID: 21678404
[TBL] [Abstract][Full Text] [Related]
9. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
[TBL] [Abstract][Full Text] [Related]
10. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
11. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by MUC1 in GEM-resistant pancreatic cancer.
Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
[TBL] [Abstract][Full Text] [Related]
12. GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
Tang Y; Cong X; Wang S; Fang S; Dong X; Yuan Y; Fan J
Biochem Biophys Res Commun; 2018 Sep; 503(4):3142-3148. PubMed ID: 30143259
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
14. Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells.
Choi MK
Arch Pharm Res; 2012 May; 35(5):921-7. PubMed ID: 22644860
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
[TBL] [Abstract][Full Text] [Related]
17. The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity.
Ramadan A; Naydenova Z; Stevanovic K; Rose JB; Coe IR
Purinergic Signal; 2014; 10(2):305-12. PubMed ID: 24163005
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
19. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
20. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
